Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
Date
2024-02-10ICR Author
Author
Mateo, J
de Bono, JS
Fizazi, K
Saad, F
Shore, N
Sandhu, S
Chi, KN
Agarwal, N
Olmos, D
Thiery-Vuillemin, A
Özgüroğlu, M
Mehra, N
Matsubara, N
Young Joung, J
Padua, C
Korbenfeld, E
Kang, J
Marshall, H
Lai, Z
Barnicle, A
Poehlein, C
Lukashchuk, N
Hussain, M
Type
Journal Article
Metadata
Show full item recordAbstract
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
Collections
Research team
PrCa Targeted Therapy
Language
eng
Date accepted
2023-08-16
License start date
2023-11-14
Citation
Journal of Clinical Oncology, 2023, pp. JCO2300339 -
Publisher
American Society of Clinical Oncology (ASCO)